Published by Ministry of Health, Labour and Welfare



Translated by Pharmaceuticals and Medical Devices Agency



This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of Precautions Radium (²²³Ra) chloride

September 18, 2018

Non-proprietary name

Radium (223Ra) chloride

Safety measure

Precautions should be revised in the package insert.

The following language should be added to the Important Precautions section (revised language is underlined):

A clinical study investigating administration of this drug or a placebo in combination with abiraterone acetate plus prednisone (currently unapproved in Japan) or prednisolone to chemotherapy-naïve patients with asymptomatic or mildly symptomatic castration-resistant prostate cancer accompanied by bone metastases showed a tendency for a higher mortality rate and incidence of bone fracture after receiving this drug compared to the patients who were given a placebo. Based on these findings, co-administration of this drug with abiraterone acetate and prednisolone is not recommended in chemotherapy-naïve patients with asymptomatic or mildly symptomatic castration-resistant prostate cancer accompanied by bone metastases.

> Pharmaceuticals and Medical Devices Agency Office of Safety I 3·3·2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan E-mail: <u>safety.info@pmda.go.jp</u>